API | orteronel

orteronel Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Orteronel (TAK-700) is a nonsteroidal CYP17A1 inhibitor that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals. It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result. ^Wikipedia

Chemistry

SMILES: CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1
InChIKey: OZPFIJIOIVJZMN-SFHVURJKSA-N
Mol. Mass: 307.35
ALogP: 2.04 Partition coefficient
ChEMBL Molecule:
orteronel

More Chemistry

Pharmacology

Mechanism of Action:
- Steroid 17-alpha-hydroxylase/17,20 lyase (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

6-((7s)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-n-methyl-2-naphthamide | orteronel | orteronel, (r)- | tak-700

Organizations (28)

Research & Development (28)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Breast Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 19
# of Trial Organizations: 28

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue